# Peter F Ambros

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 187 papers | 13,574 citations | 54 h-index | 114 g-index |
| 203 ext. papers | 15,627 ext. citations | 7.1 avg, IF | 5.57 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 187 | Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature*, **1998**, 394, 203-6 | 50.4 | 1200 |
| 186 | The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. *Journal of Clinical Oncology*, **2009**, 27, 289-97 | 2.2 | 1134 |
| 185 | The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. *New England Journal of Medicine*, **1994**, 331, 294-9 | 59.2 | 894 |
| 184 | The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. *Journal of Clinical Oncology*, **2009**, 27, 298-303 | 2.2 | 613 |
| 183 | MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. *Cancer*, **1991**, 67, 1886-93 | 6.4 | 568 |
| 182 | Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *Journal of Clinical Oncology*, **2015**, 33, 3008-17 | 2.2 | 433 |
| 181 | Chromosomally integrated human herpesvirus 6: questions and answers. *Reviews in Medical Virology*, **2012**, 22, 144-55 | 11.7 | 261 |
| 180 | Modification of DAPI banding on human chromosomes by prestaining with a DNA-binding oligopeptide antibiotic, distamycin A. *Experimental Cell Research*, **1978**, 111, 327-32 | 4.2 | 260 |
| 179 | The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 5563-8 | 11.5 | 255 |
| 178 | International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. *British Journal of Cancer*, **2009**, 100, 1471-82 | 8.7 | 255 |
| 177 | Circulating breast cancer cells are frequently apoptotic. *American Journal of Pathology*, **2001**, 159, 17-20 | 5.8 | 210 |
| 176 | Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. *New England Journal of Medicine*, **1996**, 334, 1505-11 | 59.2 | 205 |
| 175 | hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F1365-75 | 4.3 | 200 |
| 174 | Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. *Lancet Oncology, The*, **2017**, 18, 500-514 | 21.7 | 188 |
| 173 | Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Journal of Clinical Oncology*, **2011**, 29, 3286-92 | 2.2 | 187 |
| 172 | Application of Giemsa banding to orchid karyotype analysis. *Plant Systematics and Evolution*, **1980**, 134, 293-297 | 1.3 | 186 |
| 171 | Homology-dependent gene silencing in transgenic plants: epistatic silencing loci contain multiple copies of methylated transgenes. *Molecular Genetics and Genomics*, **1994**, 244, 219-29 | | 163 |

| | | | |
|---|---|---|---|
| 170 | Detection of a 17 kb unique sequence (T-DNA) in plant chromosomes by in situ hybridization. *Chromosoma*, **1986**, 94, 11-18 | 2.8 | 147 |
| 169 | Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. *Lancet Oncology, The*, **2009**, 10, 663-71 | 21.7 | 145 |
| 168 | Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. *Journal of Clinical Oncology*, **2005**, 23, 2280-99 | 2.2 | 145 |
| 167 | FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. *Cell Death and Differentiation*, **2007**, 14, 534-47 | 12.7 | 142 |
| 166 | Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1617-1629 | 21.7 | 138 |
| 165 | Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. *American Journal of Surgical Pathology*, **2006**, 30, 1462-8 | 6.7 | 136 |
| 164 | Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. *Genome Research*, **2010**, 20, 1198-206 | 9.7 | 132 |
| 163 | DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. *Nature Medicine*, **2017**, 23, 386-395 | 50.5 | 128 |
| 162 | Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. *Oncogene*, **1997**, 15, 2225-32 | 9.2 | 126 |
| 161 | Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. *Medical and Pediatric Oncology*, **2001**, 37, 492-504 | | 121 |
| 160 | Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. *British Journal of Cancer*, **2012**, 107, 1418-22 | 8.7 | 117 |
| 159 | Quality assessment of genetic markers used for therapy stratification. *Journal of Clinical Oncology*, **2003**, 21, 2077-84 | 2.2 | 109 |
| 158 | Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. *Brain Pathology*, **2003**, 13, 133-43 | 6 | 108 |
| 157 | Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. *Journal of Clinical Oncology*, **2014**, 32, 3169-76 | 2.2 | 106 |
| 156 | Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. *Genes Chromosomes and Cancer*, **1998**, 23, 141-52 | 5 | 106 |
| 155 | Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. *Oncogene*, **2001**, 20, 4402-8 | 9.2 | 100 |
| 154 | Chromosomal regions involved in the pathogenesis of osteosarcomas. *Genes Chromosomes and Cancer*, **2000**, 28, 329-36 | 5 | 96 |
| 153 | Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. *Pediatric Blood and Cancer*, **2007**, 48, 504-9 | 3 | 95 |

| | | | |
|---|---|---|---|
| 152 | Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. *British Journal of Cancer*, **2008**, 99, 1027-33 | 8.7 | 93 |
| 151 | Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. *Journal of Clinical Oncology*, **1996**, 14, 373-81 | 2.2 | 93 |
| 150 | Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. *Journal of Clinical Oncology*, **2009**, 27, 365-70 | 2.2 | 92 |
| 149 | Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. *PLoS ONE*, **2012**, 7, e31210 | 3.7 | 87 |
| 148 | Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. *British Journal of Cancer*, **1994**, 70, 908-13 | 8.7 | 86 |
| 147 | Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. *International Journal of Cancer*, **1998**, 79, 56-60 | 7.5 | 82 |
| 146 | Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. *European Journal of Cancer*, **2011**, 47, 561-71 | 7.5 | 81 |
| 145 | In vitro and in vivo profiling of P-glycoprotein in human neuroblastoma and rhabdomyosarcoma cells under simvastatin exposure. *BMC Pharmacology*, **2009**, 9, A16 | | 78 |
| 144 | Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. *Journal of Clinical Oncology*, **2011**, 29, 449-55 | 2.2 | 78 |
| 143 | Modulation of multidrug resistance proteins by statins in human neuroblastoma. *BMC Pharmacology*, **2008**, 8, A24 | | 78 |
| 142 | Prognostic impact of chromosomal aberrations in Ewing tumours. *British Journal of Cancer*, **2002**, 86, 1763-9 | 8.7 | 77 |
| 141 | Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. *Journal of Clinical Oncology*, **2016**, 34, 3195-203 | 2.2 | 75 |
| 140 | Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. *International Journal of Cancer*, **1995**, 64, 135-9 | 7.5 | 72 |
| 139 | Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13 [corrected]. *Genomics*, **1992**, 13, 219-24 | 4.3 | 68 |
| 138 | Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. *Genes Chromosomes and Cancer*, **1999**, 24, 243-54 | 5 | 67 |
| 137 | Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). *British Journal of Cancer*, **2011**, 105, 1940-8 | 8.7 | 65 |
| 136 | Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. *Genes Chromosomes and Cancer*, **1994**, 11, 40-50 | 5 | 65 |
| 135 | Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. *Oncogene*, **1999**, 18, 233-8 | 5.2 | 64 |

| | | | |
|---|---|---|---|
| 134 | Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. *Pediatric Blood and Cancer*, **2014**, 61, 627-35 | 3 | 54 |
| 133 | Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. *Cytogenetic and Genome Research*, **1993**, 63, 24-8 | 1.9 | 52 |
| 132 | Cytomegalovirus (CMV) disease of the brain in AIDS and connatal infection: a comparative study by histology, immunocytochemistry and in situ DNA hybridization. *Acta Neuropathologica*, **1989**, 79, 286-93 | 14.3 | 51 |
| 131 | Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. *Genome Research*, **1998**, 8, 929-39 | 9.7 | 50 |
| 130 | Prognostic significance of DNA di-tetraploidy in neuroblastoma. *Medical and Pediatric Oncology*, **2001**, 36, 83-92 | | 49 |
| 129 | Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. *Cancer*, **2017**, 123, 1095-1105 | 6.4 | 48 |
| 128 | Correlation of pachytene chromomeres and metaphase bands of human chromosomes, and distinctive properties of telomeric regions. *Cytogenetic and Genome Research*, **1987**, 44, 223-8 | 1.9 | 48 |
| 127 | DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. *PLoS Genetics*, **2011**, 7, e1002042 | 6 | 47 |
| 126 | Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. *Genes Chromosomes and Cancer*, **2007**, 46, 163-70 | 5 | 47 |
| 125 | Short arm dicentric Y chromosome with associated statural defects in a sterile man. *Human Genetics* , **1986**, 73, 350-3 | 6.3 | 47 |
| 124 | Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens. *Modern Pathology*, **2003**, 16, 708-15 | 9.8 | 46 |
| 123 | Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. *Journal of Clinical Oncology*, **2011**, 29, 4358-64 | 2.2 | 45 |
| 122 | Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. *Pediatric Blood and Cancer*, **2008**, 51, 589-92 | 3 | 45 |
| 121 | International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. *Journal of Clinical Oncology*, **1996**, 14, 2174-80 | 2.2 | 45 |
| 120 | Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human Schwann cell repair phenotype. *Glia*, **2016**, 64, 2133-2153 | 9 | 44 |
| 119 | Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. *Cancer*, **2016**, 122, 935-45 | 6.4 | 44 |
| 118 | Intraspinal primitive neuroectodermal tumour: report of two cases and review of the literature. *Acta Neurochirurgica*, **1999**, 141, 1169-75 | 3 | 44 |
| 117 | Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. *Journal of the National Cancer Institute*, **2018**, 110, 1084-1093 | 9.7 | 43 |

| | | | |
|---|---|---|---|
| 116 | Detection of Ip36 deletions in paraffin sections of neuroblastoma tissues. *Genes Chromosomes and Cancer*, **1993**, 6, 1-9 | 5 | 43 |
| 115 | Identification of the human homolog of the imprinted mouse Air non-coding RNA. *Genomics*, **2008**, 92, 464-73 | 4.3 | 42 |
| 114 | Detecting minimal residual disease in neuroblastoma patients-the present state of the art. *Cancer Letters*, **2005**, 228, 229-40 | 9.9 | 42 |
| 113 | Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. *International Journal of Cancer*, **2010**, 126, 2025-35 | 7.5 | 41 |
| 112 | Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. *Journal of Histochemistry and Cytochemistry*, **2005**, 53, 1433-40 | 3.4 | 39 |
| 111 | Automatic telomere length measurements in interphase nuclei by IQ-FISH. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2005**, 68, 113-20 | 4.6 | 39 |
| 110 | Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. *Medical and Pediatric Oncology*, **2000**, 35, 688-91 | | 39 |
| 109 | Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. *Oncotarget*, **2015**, 6, 35247-62 | 3.3 | 38 |
| 108 | A multilocus technique for risk evaluation of patients with neuroblastoma. *Clinical Cancer Research*, **2011**, 17, 792-804 | 12.9 | 37 |
| 107 | Demethylation of repetitive DNA sequences in neuroblastoma. *Genes Chromosomes and Cancer*, **1996**, 17, 234-44 | 5 | 37 |
| 106 | Peripheral primitive neuroectodermal tumour of the cervix. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 436, 68-73 | 5.1 | 35 |
| 105 | Chromosomal insertion of human papillomavirus 18 sequences in HeLa cells detected by nonisotopic in situ hybridization and reflection contrast microscopy. *Human Genetics*, **1987**, 77, 251-4 | 6.3 | 35 |
| 104 | Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). *Cancers*, **2020**, 12, | 6.6 | 35 |
| 103 | Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. *Frontiers in Oncology*, **2014**, 4, 202 | 5.3 | 34 |
| 102 | Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. *American Journal of Pathology*, **2003**, 163, 393-9 | 5.8 | 33 |
| 101 | Characterisation of pericentrometric and sticky intercalary heterochromatin in Ornithogalum longibracteatum (Hyacinthaceae). *Chromosoma*, **2001**, 110, 203-13 | 2.8 | 33 |
| 100 | Connatal localized neuroblastoma. The case to delay treatment. *Cancer*, **1996**, 77, 1395-401 | 6.4 | 33 |
| 99 | Neuroblastoma screening in infants postponed after the sixth month of age: a trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features. *Medical and Pediatric Oncology*, **1997**, 29, 1-10 | | 32 |

| | | | |
|---|---|---|---|
| 98 | Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of Ewing tumors. *Genes Chromosomes and Cancer*, **1996**, 17, 141-50 | 5 | 31 |
| 97 | Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. *Acta Neuropathologica Communications*, **2016**, 4, 88 | 7.3 | 31 |
| 96 | Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. *Medical and Pediatric Oncology*, **2001**, 36, 61-6 | | 30 |
| 95 | Combined restriction landmark genomic scanning and virtual genome scans identify a novel human homeobox gene, ALX3, that is hypermethylated in neuroblastoma. *Genes Chromosomes and Cancer*, **2002**, 33, 285-94 | 5 | 29 |
| 94 | Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. *Journal of Biological Chemistry*, **2001**, 276, 13192-7 | 5.4 | 29 |
| 93 | A case of trisomy 22 in Pongo pygmaeus. *Cytogenetic and Genome Research*, **1979**, 24, 1-6 | 1.9 | 29 |
| 92 | Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence. *Oncotarget*, **2016**, 7, 3571-86 | 3.3 | 29 |
| 91 | Analysis of nucleolus organizer regions (NORs) in mitotic and polytene chromosomes ofPhaseolus coccineus by silver staining and Giemsa C-banding. *Plant Systematics and Evolution*, **1979**, 132, 27-51 | 1.3 | 28 |
| 90 | Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. *British Journal of Cancer*, **2015**, 112, 290-5 | 8.7 | 27 |
| 89 | Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. *Genes Chromosomes and Cancer*, **2007**, 46, 130-42 | 5 | 27 |
| 88 | Non-random integration of Epstein-Barr virus in lymphoblastoid cell lines. *Genes Chromosomes and Cancer*, **1993**, 8, 38-48 | 5 | 27 |
| 87 | Herpes simplex virus (HSV) DNA in microglial nodular brainstem encephalitis. *Journal of Neuropathology and Experimental Neurology*, **1989**, 48, 645-52 | 3.1 | 27 |
| 86 | Translocation t(8;16) in acute monocytic leukemia. *Cancer Genetics and Cytogenetics*, **1988**, 34, 265-71 | | 27 |
| 85 | Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. *Oncology Reports*, **2005**, 13, 179-84 | 3.5 | 27 |
| 84 | Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid Biopsy Analysis. *Journal of Molecular Diagnostics*, **2020**, 22, 1070-1086 | 5.1 | 26 |
| 83 | Neuroblastoma mass screening in late infancy: insights into the biology of neuroblastic tumors. *Journal of Clinical Oncology*, **2003**, 21, 4228-34 | 2.2 | 26 |
| 82 | Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Pediatric Blood and Cancer*, **2014**, 61, 1932-9 | 3 | 25 |
| 81 | Neuroblastoma cells provoke Schwann cell proliferation in vitro. *Medical and Pediatric Oncology*, **2001**, 36, 163-8 | | 25 |

| | | | |
|---|---|---|---|
| 80 | Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis. *Cytometry*, **2000**, 42, 357-62 | | 25 |
| 79 | The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. *International Journal of Cancer*, **2016**, 139, 153-63 | 7.5 | 24 |
| 78 | Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. *Journal of Clinical Oncology*, **2020**, 38, 2902-2915 | 2.2 | 23 |
| 77 | Molecular analysis of chromosome arm 17q gain in neuroblastoma. *Genes Chromosomes and Cancer*, **2000**, 28, 276-84 | 5 | 23 |
| 76 | Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. *Journal of Clinical Oncology*, **2014**, 32, 1228-35 | 2.2 | 22 |
| 75 | Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. *American Journal of Pathology*, **2008**, 172, 203-14 | 5.8 | 21 |
| 74 | Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors. *Oncogene*, **2016**, 35, 1423-32 | 9.2 | 20 |
| 73 | Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization. *International Journal of Cancer*, **2006**, 118, 1603-8 | 7.5 | 20 |
| 72 | Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone. *Clinical Cancer Research*, **2017**, 23, 4224-4232 | 12.9 | 19 |
| 71 | Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. *International Journal of Cancer*, **2008**, 122, 1177-82 | 7.5 | 17 |
| 70 | Rapid determination of Epstein-Barr virus latent or lytic infection in single human cells using in situ hybridization. *Modern Pathology*, **2004**, 17, 1564-72 | 9.8 | 17 |
| 69 | Neuroblastoma with focal MYCN amplification and bone marrow infiltration: a staging and treatment dilemma. *Medical and Pediatric Oncology*, **2002**, 38, 109-11 | | 17 |
| 68 | Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. *Nature Communications*, **2021**, 12, 3230 | 17.4 | 17 |
| 67 | Genetic changes of two Wilms tumors with anaplasia and a review of the literature suggesting a marker profile for therapy resistance. *Cancer Genetics and Cytogenetics*, **2002**, 135, 128-38 | | 16 |
| 66 | Loss of the p16/MTS1 tumor suppressor gene causes E2F-mediated deregulation of essential enzymes of the DNA precursor metabolism. *DNA and Cell Biology*, **1996**, 15, 41-51 | 3.6 | 16 |
| 65 | Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8. *Nature Communications*, **2021**, 12, 1624 | 17.4 | 16 |
| 64 | Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. *Molecular Oncology*, **2015**, 9, 545-54 | 7.9 | 15 |
| 63 | An annotated fluorescence image dataset for training nuclear segmentation methods. *Scientific Data*, **2020**, 7, 262 | 8.2 | 15 |

| | | | |
|---|---|---|---|
| 62 | Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. *British Journal of Cancer*, **2018**, 118, 1502-1512 | 8.7 | 15 |
| 61 | Disseminated tumor cells in the bone marrow - chances and consequences of microscopical detection methods. *Cancer Letters*, **2003**, 197, 29-34 | 9.9 | 14 |
| 60 | Automatic detection and genetic profiling of disseminated neuroblastoma cells. *Medical and Pediatric Oncology*, **2001**, 36, 205-9 | | 14 |
| 59 | Translocation (12;13) in a case of infantile fibrosarcoma. *Cancer Genetics and Cytogenetics*, **1993**, 71, 94-6 | | 14 |
| 58 | Interphase cytogenetic study of childhood acute lymphoblastic leukemia. *Medical and Pediatric Oncology*, **1994**, 23, 413-21 | | 14 |
| 57 | Isochromosome 12p and maternal loss of 1p36 in a pediatric testicular germ cell tumor. *Cancer Genetics and Cytogenetics*, **1996**, 91, 95-100 | | 13 |
| 56 | Comparison of in situ DNA hybridization (ISH) and immunocytochemistry for diagnosis of herpes simplex virus (HSV) encephalitis in tissue. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1988**, 414, 39-43 | | 13 |
| 55 | Detailed Protocols for the Isolation, Culture, Enrichment and Immunostaining of Primary Human Schwann Cells. *Methods in Molecular Biology*, **2018**, 1739, 67-86 | 1.4 | 12 |
| 54 | Biological aspects of neuroblastoma screening. *Medical and Pediatric Oncology*, **1998**, 31, 394-400 | | 12 |
| 53 | Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications. *Clinical Cancer Research*, **2004**, 10, 6567-71 | 12.9 | 12 |
| 52 | Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt lymphoma, and Hodgkin lymphoma. *Annals of Hematology*, **2002**, 81, 441-7 | 3 | 12 |
| 51 | Immunoenzymatic staining methods for simultaneous demonstration of chromosomes and cell surface markers. *Cancer Genetics and Cytogenetics*, **1987**, 27, 229-40 | | 12 |
| 50 | Trisomy 14 in refractory anemia with excess of blasts in transformation. *Cancer Genetics and Cytogenetics*, **1987**, 29, 315-8 | | 12 |
| 49 | Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. *Nature Communications*, **2021**, 12, 1269 | 17.4 | 12 |
| 48 | Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. *European Journal of Cancer*, **2012**, 48, 1185-91 | 7.5 | 11 |
| 47 | Automatic quantification of gene amplification in clinical samples by IQ-FISH **2004**, 57, 15-22 | | 11 |
| 46 | DEC1 expression in 1p-aberrant oligodendroglial neoplasms. *Histology and Histopathology*, **2005**, 20, 1173-7 | 1.4 | 11 |
| 45 | Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. *International Journal of Cancer*, **2018**, 142, 297-307 | 7.5 | 10 |

| | | | |
|---|---|---|---|
| 44 | Metastatic extraosseous Ewing tumor. Association of the additional translocation der(16)t(1;16) with the variant EWS/ERG rearrangement in a case of cytogenetically inconspicuous chromosome 22. *Cancer Genetics and Cytogenetics*, **1996**, 87, 161-6 | | 10 |
| 43 | Evaluation of Deep Learning Architectures for Complex Immunofluorescence Nuclear Image Segmentation. *IEEE Transactions on Medical Imaging*, **2021**, 40, 1934-1949 | 11.7 | 10 |
| 42 | Molecular analysis of the putative tumour-suppressor gene EXTL1 in neuroblastoma patients and cell lines. *European Journal of Cancer*, **2004**, 40, 1255-61 | 7.5 | 9 |
| 41 | In situ reverse-transcriptase polymerase chain reaction demonstration of the EWS/FLI-1 fusion transcript in Ewing's sarcomas and peripheral primitive neuroectodermal tumors. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 437, 234-40 | 5.1 | 9 |
| 40 | Neuroblastoma with N-myc amplification detected by urine: mass screening in infants after the sixth month of life. *Medical and Pediatric Oncology*, **1993**, 21, 625-6 | | 9 |
| 39 | Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. *Journal of Clinical Oncology*, **2021**, 39, 2552-2563 | 2.2 | 9 |
| 38 | Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. *Nature Communications*, **2021**, 12, 6804 | 17.4 | 8 |
| 37 | Classification of isolated tumor cells and micrometastasis. *Cancer*, **2000**, 89, 709-11 | 6.4 | 7 |
| 36 | Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front□ne high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.. *Journal of Clinical Oncology*, **2019**, 37, 10013-10013 | 2.2 | 7 |
| 35 | A new platform linking chromosomal and sequence information. *Chromosome Research*, **2007**, 15, 327-39 | 4.4 | 5 |
| 34 | Detection and relocation of rare events. A comparative study using the laser scanning cytometer and the Metafer/RCDetect microscope scanning system. *Journal of Proteomics*, **2002**, 53, 109-15 | | 5 |
| 33 | Immunotherapy with anti-GD2 antibody ch14.18/CHO□IL2 within the HR-NBL1/SIOPEN trial to improve outcome of high-risk neuroblastoma patients compared to historical controls.. *Journal of Clinical Oncology*, **2018**, 36, 10539-10539 | 2.2 | 5 |
| 32 | Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies-A Validation Study. *PLoS ONE*, **2015**, 10, e0137995 | 3.7 | 5 |
| 31 | Frequency and Prognostic Impact of Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). *Journal of Clinical Oncology*, **2021**, 39, 3377-3390 | 2.2 | 5 |
| 30 | Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma. *European Journal of Cancer*, **2014**, 50, 622-7 | 7.5 | 4 |
| 29 | Sequence based high resolution chromosomal CGH. *Cytogenetic and Genome Research*, **2008**, 121, 1-6 | 1.9 | 4 |
| 28 | Autologous rescue with blood-derived stem cells in a child with non-Hodgkin's lymphoma. *Pediatric Hematology and Oncology*, **1990**, 7, 137-44 | 1.7 | 4 |
| 27 | Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors. *PLoS ONE*, **2016**, 11, e0161369 | 3.7 | 4 |

| | | | |
|---|---|---|---|
| 26 | Machine learning framework incorporating expert knowledge in tissue image annotation **2016**, | | 4 |
| 25 | Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines*□**2001**, 37, 492 | | 4 |
| 24 | Frequent low level expression in Ewing sarcoma family tumors and widespread absence of the metastasis suppressor KAI1/CD82 in neuroblastoma. *Pediatric Research*, **2002**, 52, 279-85 | 3.2 | 3 |
| 23 | Immunotherapy (IT) with ch14.18/CHO for high-risk neuroblastoma: First results from the randomised HR-NBL1/SIOPEN trial.. *Journal of Clinical Oncology*, **2014**, 32, 10026-10026 | 2.2 | 3 |
| 22 | SKY analysis of childhood neural tumors and cell lines demonstrates a susceptibility of aberrant chromosomes to further rearrangements. *Cancer Letters*, **2007**, 250, 47-52 | 9.9 | 2 |
| 21 | Treatment of Neuroblastoma. *Pediatric Oncology*, **2005**, 123-192 | 0.5 | 2 |
| 20 | Double-target FISH in the diagnosis of Ewing tumors. *Cancer Genetics and Cytogenetics*, **1994**, 77, 202 | | 2 |
| 19 | Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma. *Journal of Cancer Research and Clinical Oncology*, **2021**, 1 | 4.9 | 2 |
| 18 | Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. *Journal of Clinical Oncology*, **2020**, 38, 3685-3697 | 2.2 | 2 |
| 17 | DeepSNP: An End-to-End Deep Neural Network with Attention-Based Localization for Breakpoint Detection in Single-Nucleotide Polymorphism Array Genomic Data. *Journal of Computational Biology*, **2019**, 26, 572-596 | 1.7 | 2 |
| 16 | Semi-automated segmentation of neuroblastoma nuclei using the gradient energy tensor: a user driven approach **2015**, | | 1 |
| 15 | Free DNA in the blood serum can unmask MYCN amplified tumors. *Pediatric Blood and Cancer*, **2009**, 53, 306-7 | 3 | 1 |
| 14 | Neuroblastome **2006**, 829-846 | | 1 |
| 13 | Treatment complications in neuroblastoma patients: lessons from screening studies. *Journal of Clinical Oncology*, **2006**, 24, e41 | 2.2 | 1 |
| 12 | Neuroblastoma screening in early life. *New England Journal of Medicine*, **2002**, 347, 852-4; author reply 852-4 | 59.2 | 1 |
| 11 | Localization of the human I-kappaB kinase-beta (IKBKB) to chromosome 8p11.2 by fluorescence in situ hybridization and radiation hybrid mapping. *Genomics*, **1998**, 54, 575-6 | 4.3 | 1 |
| 10 | Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8 | | 1 |
| 9 | The Ig Heavy Chain 3? End Confers a Posttranscriptional Processing Advantage to Bcl-2□gH Fusion RNA in t(14;18) Lymphoma. *Blood*, **1998**, 91, 3952-3961 | 2.2 | 1 |

| | | | |
|---|---|---|---|
| 8 | Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 7 | Connatal localized neuroblastoma: The case to delay treatment **1996**, 77, 1395 | | 1 |
| 6 | Sequence-based high resolution chromosomal comparative genomic hybridization (CGH). *Methods in Molecular Biology*, **2010**, 659, 299-312 | 1.4 | |
| 5 | Neuroblastoma screening for children: delay, repeat, or delete?. *Medical and Pediatric Oncology*, **1998**, 31, 111-2 | | |
| 4 | Clinical appearance of neuroblastoma 10 years after screening. *Pediatric Blood and Cancer*, **2007**, 49, 1012-4 | 3 | |
| 3 | Combined immunofluorescence and FISH: new prospects for tumor cell detection/identification. *Current Protocols in Cytometry*, **2004**, Chapter 8, Unit 8.13 | 3.6 | |
| 2 | Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?. *Journal of Clinical Oncology*, **2018**, 36, 10550-10550 | 2.2 | |
| 1 | Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. *Journal of Clinical Oncology*, **2013**, 31, 10015-10015 | 2.2 | |